SEARCH

SEARCH BY CITATION

References

  • 1
    Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 10891100.
  • 2
    Myers BD, Ross JC, Newton LD, Luetscher JA, Perlroth MG. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 600705.
  • 3
    Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 11411151.
  • 4
    Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 21472159.
  • 5
    Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in chronic cyclosporine nephropathy. Kidney Int 1997; 52: 660673.
  • 6
    Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 11741185.
  • 7
    Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 12861292.
  • 8
    Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta-1. Nature 1990; 346: 371374.
  • 9
    Akagi Y, Isaka Y, Arai M et al. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148155.
  • 10
    Border WA, Noble NA, Yamamato T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361364.
  • 11
    Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418423.
  • 12
    Isaka Y, Akagi Y, Ando Y et al. Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999; 55: 465475.
  • 13
    Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri S. Dietary intake of pirfenidone ameliorates bleomycin induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125: 779785.
  • 14
    Suga H, Teraoka S, Oka K et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxic Pathol 1995; 47: 287292.
  • 15
    Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med 1999; 159: 10611069.
  • 16
    Shimizu F, Fukagawa M, Yamauchi S et al. Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions. Nephrol 1997; 3: 315322.
  • 17
    Shimizu T, Fukagawa M, Kuroda T et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 1997; 52: S239S243.
  • 18
    Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99109.
  • 19
    Fukagawa M, Noda M, Shimizu T, Kurokawa K. Chronic progressive interstitial fibrosis in renal disease – are there novel pharmacologic approaches? Nephrol Dial Transplant 1999; 14: 27932795.
  • 20
    Iyer SN, Gurujeyalakshmi G, Siri SN. Effect of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367373.
  • 21
    Iyer SN, Gurujeyalakshmi G, Siri SN. Effect of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 289: 211218.
  • 22
    Derynck R, Jarrett JA, Chen EY, Goeddel DV. The murine transforming growth factor-β precursor. J Biol Chem 1986; 261: 43774379.
  • 23
    Zeheb R, Gelehrter TD. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988; 73: 459468.
  • 24
    Fisher LW, Termine JD, Young MF. Deduced protein sequence of small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 1989; 264: 45714576.
  • 25
    Fort P, Marty L, Piechaczyk M et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family. Nucl Acid Res 1985; 13: 14311442.
  • 26
    Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. Transplantation 1990; 49: 445452.
  • 27
    Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 24952508.
  • 28
    Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new DNA synthesis in mammalian cells by cyclosporine. Transplantation 1994; 57: 577582.
  • 29
    Noble NA, Border WA. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol 1997; 17: 455466.
  • 30
    Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA. Dietary protein restriction rapidly reduces transforming growth factor β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 1991; 88: 97659769.
  • 31
    Reyes AA, Pukerson ML, Karl I, Klahr S. Dietary supplementation with l-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992; 20: 168176.
  • 32
    Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133: 687694.
  • 33
    Khalil N, Corne S, Whitman C, Yacyshyn H. Plasmin regulates the activation of latent TGF-β secreted by alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol 1996; 15: 252259.
  • 34
    Lee BS, Margolin SB, Nowak RA, Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998; 83: 219223.
  • 35
    Armendariz-Borunda J, Katayama K, Seyer JM. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1β, tumor necrosis factor α, and transforming growth factor β in Ito cells. J Biol Chem 1992; 267: 1431614321.
  • 36
    Amento EP, Bhan AK, McCullagh KG, Krane SM. Influences of gamma interferon on synovial fibroblastlike cells. Ia induction and inhibition of collagen synthesis. J Clin Invest 1985; 76: 837848.
  • 37
    Young B, Burdmann EA, Johnson RJ et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439448.
  • 38
    Schegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin induced changes in pulmonary function in hamsters. Proc Soc Exp Biol Med 1997; 216: 392397.
  • 39
    Dosanjh AK, Wan B, Throndset W, Sherwood S, Morris RE. Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proc 1998; 30: 19101911.
  • 40
    Kaneko M, Inoue H, Nakazawa R et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) downregulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 7276.
  • 41
    Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three dose bleomycin hamster model. Exp Lung Res 1998; 24: 119132.